104 related articles for article (PubMed ID: 25074720)
1. Preparation and radiolabeling of a lyophilized (kit) formulation of DOTA-rituximab with ⁹⁰Y and ¹¹¹In for domestic radioimmunotherapy and radioscintigraphy of non-Hodgkin's lymphoma.
Gholipour N; Jalilian AR; Khalaj A; Johari-Daha F; Yavari K; Sabzevari O; Khanchi AR; Akhlaghi M
Daru; 2014 Jul; 22(1):58. PubMed ID: 25074720
[TBL] [Abstract][Full Text] [Related]
2. Comparison of (64)Cu-complexing bifunctional chelators for radioimmunoconjugation: labeling efficiency, specific activity, and in vitro/in vivo stability.
Cooper MS; Ma MT; Sunassee K; Shaw KP; Williams JD; Paul RL; Donnelly PS; Blower PJ
Bioconjug Chem; 2012 May; 23(5):1029-39. PubMed ID: 22471317
[TBL] [Abstract][Full Text] [Related]
3. Preparation and preliminary bioevaluation studies of
Suman SK; Kameswaran M; Pandey U; Sarma HD; Dash A
J Labelled Comp Radiopharm; 2019 Oct; 62(12):850-859. PubMed ID: 31461549
[TBL] [Abstract][Full Text] [Related]
4. Development of humoral immune responses against a macrocyclic chelating agent (DOTA) in cancer patients receiving radioimmunoconjugates for imaging and therapy.
Kosmas C; Snook D; Gooden CS; Courtenay-Luck NS; McCall MJ; Meares CF; Epenetos AA
Cancer Res; 1992 Feb; 52(4):904-11. PubMed ID: 1737353
[TBL] [Abstract][Full Text] [Related]
5. Preparation of
Pandey U; Kameswaran M; Gamre N; Dash A
J Labelled Comp Radiopharm; 2019 Apr; 62(4):158-165. PubMed ID: 30663095
[TBL] [Abstract][Full Text] [Related]
6. Impact of DOTA-Chelators on the Antitumor Activity of
Wojdowska W; Karczmarczyk U; Balog L; Sawicka A; Pöstényi Z; Kovács-Haász V; Polyák A; Laszuk E; Mikołajczak R; Garnuszek P
Cancer Biother Radiopharm; 2020 Oct; 35(8):558-562. PubMed ID: 32255676
[No Abstract] [Full Text] [Related]
7. 90Y Labeling of monoclonal antibody MOv18 and preclinical validation for radioimmunotherapy of human ovarian carcinomas.
Coliva A; Zacchetti A; Luison E; Tomassetti A; Bongarzone I; Seregni E; Bombardieri E; Martin F; Giussani A; Figini M; Canevari S
Cancer Immunol Immunother; 2005 Dec; 54(12):1200-13. PubMed ID: 15926078
[TBL] [Abstract][Full Text] [Related]
8. Effect of Number of Bifunctional Chelating Agents on the Pharmacokinetics and Immunoreactivity of 177Lu-labeled Rituximab: A Systemic Study.
Guleria M; Das T; Kumar C; Sharma R; Amirdhanayagam J; Sarma HD; Dash A
Anticancer Agents Med Chem; 2018; 18(1):146-153. PubMed ID: 28745238
[TBL] [Abstract][Full Text] [Related]
9. Influence of DOTA Chelators on Radiochemical Purity and Biodistribution of
Karczmarczyk U; Wojdowska W; Mikołajczak R; Maurin M; Laszuk E; Garnuszek P
Iran J Pharm Res; 2018; 17(4):1201-1208. PubMed ID: 30568680
[TBL] [Abstract][Full Text] [Related]
10. DTPA(DOTA)-Nimotuzumab Radiolabeling with Generator-produced Thorium for Radioimmunotherapy of EGFR-overexpressing Carcinomas.
Bravo MG; Egorova BV; Vasiliev AN; Lapshina EV; Ermolaev SV; Durymanov MO
Curr Radiopharm; 2023 Jun; 16(3):233-242. PubMed ID: 36809934
[TBL] [Abstract][Full Text] [Related]
11. Panitumumab Modified with Metal-Chelating Polymers (MCP) Complexed to
Aghevlian S; Lu Y; Winnik MA; Hedley DW; Reilly RM
Mol Pharm; 2018 Mar; 15(3):1150-1159. PubMed ID: 29314858
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of
Banerjee SR; Kumar V; Lisok A; Plyku D; Nováková Z; Brummet M; Wharram B; Barinka C; Hobbs R; Pomper MG
J Nucl Med; 2019 Mar; 60(3):400-406. PubMed ID: 30237212
[TBL] [Abstract][Full Text] [Related]
13. Development of DOTA-Rituximab to be Labeled with
Johari Doha F; Rahmani S; Rikhtechi P; Rasaneh S; Sheikholislam Z; Shahhosseini S
Iran J Pharm Res; 2017; 16(2):619-629. PubMed ID: 28979315
[TBL] [Abstract][Full Text] [Related]
14. Preclinical Characterization of the Radioimmunoconjugate
Funase Y; Nakamura E; Kajita M; Saito Y; Oshikiri S; Kitano M; Tokura M; Hino A; Uehara T
J Nucl Med; 2021 Feb; 62(2):232-239. PubMed ID: 32737245
[TBL] [Abstract][Full Text] [Related]
15.
Scotognella T; Maccora D; Bruno I; Chinol M; Castagnola M; Collamati F; Mancini-Terraciano C; Morganti S; Bocci V; Camillocci ES; Rotili D; Cartoni A; Fratoddi I; Marini F; Venditti I; Faccini R; Giordano A
Curr Radiopharm; 2022; 15(1):32-39. PubMed ID: 33397277
[TBL] [Abstract][Full Text] [Related]
16. Lyophilization of NOTA-sdAbs: First step towards a cold diagnostic kit for
Baudhuin H; Van Bockstal PJ; De Beer T; Vaneycken I; Bridoux J; Raes G; Caveliers V; Keyaerts M; Devoogdt N; Lahoutte T; Xavier C
Eur J Pharm Biopharm; 2021 Sep; 166():194-204. PubMed ID: 34186190
[TBL] [Abstract][Full Text] [Related]
17. Intricacies in the Preparation of Patient Doses of [
Chakraborty A; Mitra A; Sahu S; Tawate M; Lad S; Kamaldeep ; Rakshit S; Upadhye Bannore T; Gaikwad S; Dhotre G; Ray MK; Damle A; Basu S; Banerjee S
Mol Imaging Biol; 2024 Feb; 26(1):61-80. PubMed ID: 37673943
[TBL] [Abstract][Full Text] [Related]
18. Anti-CD45 radioimmunotherapy with 90Y but not 177Lu is effective treatment in a syngeneic murine leukemia model.
Orozco JJ; Balkin ER; Gooley TA; Kenoyer A; Hamlin DK; Wilbur DS; Fisher DR; Hylarides MD; Shadman M; Green DJ; Gopal AK; Press OW; Pagel JM
PLoS One; 2014; 9(12):e113601. PubMed ID: 25460570
[TBL] [Abstract][Full Text] [Related]
19. Reduction of the hepatic radioactivity levels of [
Suzuki H; Matsukawa M; Madokoro R; Terasaka Y; Kannaka K; Uehara T
Nucl Med Biol; 2024; 132-133():108910. PubMed ID: 38636351
[TBL] [Abstract][Full Text] [Related]
20. AAZTA
Klasen B; Moon ES; Rösch F
Nucl Med Biol; 2021; 96-97():80-93. PubMed ID: 33839678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
